Track Record
Michael Atkin Deal Sheet
Catalyst merger, consumer product divestitures, chemical/defense M&A and 16 life sciences partnerships (excluding university licenses): >$2 billion in value generation, aggregate proceeds and realized returns.
16 Life Sciences Partnerships
| Deal Value | Deal Type | Atkin Represented | Partner | Atkin Role | Notes |
|---|---|---|---|---|---|
| $930m of value added (>2x increase) | Catalyst merger UOP & CAPS | American Cyanamid: UOP | Union Carbide’s Catalyst, Adsorbent & Process Systems | Valuations, diligence and implementation. Legal, tax & treasury coordination. Obtained 9-figure non-recourse loan | Honeywell acquired Union-Carbide’s 50% interest for $825m, firm value $1.65b |
| ≥$850m proceeds: P&G $370m, Clorox $465m, NY Times est. Cardin rights @ $50m | Consumer product divestitures | American Cyanamid sold Old Spice, Pine-Sol, Combat, Breck, Pierre Cardin & Maxim’s brands. | P&G, Clorox, Greyhound Dial, Pierre Cardin | Worked closely with Morgan Stanley; data room; trouble-shooting at negotiating table. Settled 2 lawsuits, negotiated 2 fragrance deals with Mr. Cardin. | Full-time job for 1 year |
| $350m for 53.5% stake | Oncology acquisition | Lederle International | Immunex | Int’l. rights valuation & integration; VP BD | |
| >Bio$35m, upfront, royalty and milestones | Stem cell SKP out-license from adult human skin | Aegera Therapeutics | Curis | Negotiator, Aegera CEO and funded Miller/Kaplan lab. stem cell studies | Freda Miller, PhD & David Kaplan, PhD invention |
| Not publicly disclosed (NPD) | Aerospace composite fabricator acquisition | Allied-Signal Engineered Materials | KDI Composite Technology, Inc. | NPV spreadsheet jockey. Supported due diligence, bid and term sheet | |
| NPD | Sale of Canadian chemical plant | American Cyanamid | Carbon Graphite Group (SKW) | Valuation, negotiation, term sheet, diligence. Banker: Oppenheimer | |
| NPD | Licensed int’l. leukemia pentostatin rights | Lederle Int’l. | Warner-Lambert | Co-lead, Director BD | Oncology sales reps needed a new product |
| NPD | Licensed NS2214 (BMS-204756) for PD | BMS neuroscience group | NeuroSearch | Co-lead w/ BMS licensing Ex. Director | Parkinson’s Disease |
| >5x sales | Sold derm prod | Lederle Int’l. | Galderma | Co-lead, Director BD | |
| NPD | In-licensed antisense platform & research agt | Aegera Therapeutics Inc. | Idera | Negotiator, Aegera CEO. Worked closely with Idera till IND filed | Advanced AEG-35156 oligo to oncology trials in Canada, UK & US |
| Equity + $7.5m in milestones | Purchased Xeno Biosciences clinical & preclinical data and IP | LPOXY Therapeutics Inc. | Xeno Biosciences and investors | Negotiator, Board Chair. Wrote and negotiated term sheet, finalized deal. Catapulted LPOXY to clinical stage firm. | Firms used same API to generate oxygen in the gut. Obesity → C. Diff. prevention |
| $10m upfront + milestones & ctments | Out-licensed cethrin for spinal cord injury | BioAxone | Alseres | Supported CEO in negotiations as board member | |
| NPD | Merger of 2 biotech firms | Exogen Neurosciences | Apoptogen Inc. | Negotiator. Exogen CEO, Aegera Therapeutics CEO | Formed Aegera Therapeutics, apoptosis induction focus |
| NPD equity | Sold angel-backed ID technology to startup | Sopharmia | Gladius Pharmaceuticals funded by SR One, Lumira Capital and FSTQ | Negotiator. Sopharmia Chair & Gladius CEO | $4m+ financing disclosed |
| NPD | Renegotiated supply agt. | Lederle Int’l. | Merck Eprova | Co-lead, Director BD | Renegotiated new supply agt. for chiral oncology product |
| NPD | Renegotiated antibiotic free goods contract | Lederle Int’l. | Fujisawa Pharmaceutical Co. Ltd. | Co-lead, Director BD | Improved antibiotic deal terms |
| NPD | 4 Out-licenses for research tools access | Aegera Therapeutics Inc. | HGS, Wyeth, Millennium, BD [4 separate deals] | Negotiator, Aegera CEO | Introduced picomolar XIAP inhibitor program to HGS – $20m upfront deal finalized after left firm: not included in the deal count |
Blue rows: life sciences partnerships · NPD: Not publicly disclosed
Let's Connect
Let's align strategy with opportunity.
For clinical and pre-IND life sciences companies seeking the right strategic partnership.